ISSN (print) 1726-9806     ISSN (online) 1818-474X
No. 1 (2024), CLINICAL GUIDELINES
No. 1 (2024)
CLINICAL GUIDELINES

Perioperative management of patients with hemostatic system disorders. Methodological recommendations of the All-Russian public organization “Federation of Anesthesiologists and Reanimatologists” and the National Association of Specialists in Thrombosis, Clinical Hemostasiology and Hemorheology

Published 27.01.2024
Igor B. Zabolotskikh
Kuban State Medical University, Krasnodar, Russia; Krasnodar Regional Hospital No. 2, Krasnodar, Russia; Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia
https://orcid.org/0000-0002-3623-2546
S.V. Sinkov
Kuban State Medical University, Krasnodar, Russia; Krasnodar Regional Hospital No. 2, Krasnodar, Russia
https://orcid.org/0000-0003-4483-4077
A.Yu. Bulanov
N.V. Sklifosovsky Research Institute for Emergency Medicine, Moscow, Russia
https://orcid.org/0000-0001-6999-8145
N.A. Vorobyova
Northern State Medical University, Arkhangelsk, Russia
https://orcid.org/0000-0001-6613-2485
A.A. Eremenko
Petrovsky National Research Centre of Surgery, Moscow, Russia
https://orcid.org/0000-0001-5809-8563
A.N. Kuzovlev
Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia
https://orcid.org/0000-0002-5930-0118
A.V. Kulikov
State Medical University, Yekaterinburg, Russia
https://orcid.org/0000-0002-7768-4514
K.M. Lebedinskii
Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia; North-Western State Medical University named after I.I. Mechnikov, St. Petersburg, Russia
https://orcid.org/0000-0002-5752-4812
A.S. Popov
Volgograd State Medical University, Volgograd, Russia
https://orcid.org/0000-0003-2241-8144
E.V. Roitman
Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia
https://orcid.org/0000-0002-3015-9317
PDF_2024-1_7-46 (Russian)
HTML_2024-1_7-46_S (Russian)

Keywords

disseminated intravascular coagulation syndrome
hepatic coagulopathy
uremic coagulopathy
traumatic (hemodilution) coagulopathy
thrombocytopenia
thrombocytopathy
acquired disorders of the hemostatic system
hereditary disorders of the hemostatic system
antiphospholipid syndrome
hemophilia
von Willebrand disease
perioperative monitoring
acute massive blood loss
shock

How to Cite

1.
Zabolotskikh I.B., Sinkov S.V., Bulanov A.Y., Vorobyova N.A., Eremenko A.A., Kuzovlev A.N., Kulikov A.V., Lebedinskii K.M., Popov A.S., Roitman E.V. Perioperative management of patients with hemostatic system disorders. Methodological recommendations of the All-Russian public organization “Federation of Anesthesiologists and Reanimatologists” and the National Association of Specialists in Thrombosis, Clinical Hemostasiology and Hemorheology. Annals of Critical Care. 2024;(1):7-46. doi:10.21320/1818-474X-2024-1-7-46
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Statistic

Abstract Views: 759
PDF_2024-1_7-46 (Russian) Downloads: 293
HTML_2024-1_7-46_S (Russian) Downloads: 64
Statistic from 01.07.2024

Language

English Русский

Most reader

Social Networks

Abstract

Perioperative coagulation disorders pose a serious risk of life-threatening complications. The article presents methodological recommendations of the Federation of Anesthesiologists and reanimatologists of Russian Federation for the perioperative management of patients with disorders of the hemostatic system, which summarizes aspects of both diagnosis and assessment, and intensive care of congenital and acquired disorders of the coagulation system in the perioperative period. The literature search focused on meta-analyses and randomized controlled trials, but also included registries, non-randomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion. The principles of perioperative management of disseminated intravascular coagulation syndrome, hepatic, uremic, traumatic, septic coagulopathy, acquired thrombocytopenia and trobocytopathies, antiphospholipid syndrome, hemophilia A and B, von Willebrand disease and other pathologies are described. For each recommendation, the level of certainty of the evidence and the level of strength of the evidence are presented. The recommendations were developed by experts in the field of perioperative patient management for anesthesiologists and intensive care physicians as a help in making clinical decisions; the final decision for a particular patient is made by the attending physician.

PDF_2024-1_7-46 (Russian)
HTML_2024-1_7-46_S (Russian)

Full-text of the article is available for this locale: Russian.

References

  1. Kitchens C.S. Disseminated Intravascular Coagulation. In: Kitchens C.S. Ed. Consultative Hemostasis and Thrombosis. W.B.: Saunders Company. 2007; 165–78.
  2. Ralph A.G., Brainard B.M. Update on disseminated intravascular coagulation: when to consider it, when to expect it, when to treat it. Top Companion Anim Med. 2012; 27(2): 65–72. DOI: 10.1053/j.tcam.2012.06.004
  3. Asakura H. Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care. 2014; 2(1): 20. DOI: 10.1186/2052-0492-2-20
  4. Thachil J., Falanga A., Levi M., et al. Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH. J Thromb Haemost. 2015; 13(4): 671–5. DOI: 10.1111/jth.12838
  5. Kaneko T., Wada H. Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. J Clin Exp Hematop. 2011; 51(2): 67–76. DOI: 10.3960/jslrt.51.67
  6. Воробьева Н.А., Капустин С.И. Роль генетических полиморфизмов системы гемостаза в формировании полиорганной недостаточности при остром ДВС-синдроме. Анестезиология и реаниматология. 2007; 2: 52–5. [Vorob’eva N.A., Kapustin S.I. Rol’ geneticheskih polimorfizmov sistemy gemostaza v formirovanii poliorgannoj nedostatochnosti pri Ostrom DVS-sindrome. Anesteziologiya i reanimatologiya. 2007;2:52-55. (In Russ)]
  7. Taylor F.B. Jr, Toh C.H., Hoots W.K., et al. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001; 86(5): 1327–30.
  8. Blasi A. Coagulopathy in liver disease: Lack of an assessment tool. World J Gastroenterol. 2015; 21(35): 10062–71. DOI: 10.3748/wjg.v21.i35.10062
  9. Uijttewaal W.S., Nijhof E.J., Bronkhorst P.J., et al. Near-wall excess of platelets induced by lateral migration of erythrocytes in flowing blood. Am J Physiol. 1993; 264(4, Pt. 2): H1239-H1244. DOI: 10.1152/ajpheart.1993.264.4.H1239
  10. Peyrou V., Lormeau J.C., Hérault J.P., et al. Contribution of erythrocytes to thrombin generation in whole blood. Thromb Haemost. 1999; 81(3): 400–6.
  11. Sagesaka T. Influence of red blood cell concentration on the initiation time of blood coagulation: risk of thrombus formation by hemoconcentration. Clin Hemorheol Microcirc. 2004; 31(4): 243–9.
  12. Boccardo P., Remuzzi G., Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost. 2004; 30(5): 579–89. DOI: 10.1055/s-2004-835678
  13. Rossaint R., Bouillon B., Cerny V., et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care. 2016; 20: 100. DOI: 10.1186/s13054-016-1265-x
  14. Dyer M.R., Plautz W.E., Ragni M.V., et al. Traumatic injury results in prolonged circulation of ultralarge von Willebrand factor and a reduction in ADAMTS13 activity. Transfusion. 2020; 60(6): 1308–18. DOI: 10.1111/trf.15856
  15. Deloughery T.G. Hemorrhagic and Thrombotic Disorders in the Intensive Care Setting. In: Kitchens C.S., Ed. Consultative Hemostasis and Thrombosis. W.B.: Saunders Company. 2007; 493–514.
  16. Marcucci C.E., Schoettker P. Perioperative Hemostаsis. Springer; 2015. 454 p.
  17. Antiphospholipid Syndrome: Insights and Highlights from the 13th International Congress on Antiphospholipid Antibodies. Eds. Erkan D. and Pierangeli S.S. DOI: 10.1007/978-1-4614-3194-7_17, Springer Science+Business Media New York 2012
  18. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2): 295–306. DOI: 10.1111/j.1538-7836.2006.01753.x
  19. Asherson R.A., Cervera R., de Groot P.G., et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003; 12(7): 530–4. DOI: 10.1191/0961203303lu394oa
  20. Kitchens C.S. Surgery and hemostasis. In: Kitchens C.S. Ed. Consultative Hemostasis and Thrombosis. W.B.: Saunders Company; 2007; 463–80.
  21. Srivastava A., Brewer A.K., Mauser-Bunschoten E.P., et al. Guidelines for the management of hemophilia. Haemophilia. 2013; 19(1): e1–e47. DOI: 10.1111/j.1365-2516.2012.02909.x
  22. Blanchette V.S., Key N.S., Ljung L.R., et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014; 12(11): 1935–9. DOI: 10.1111/jth.12672
  23. Laffan M.A., Lester W., O'Donnell J.S., et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014; 167(4): 453–65. DOI: 10.1111/bjh.13064
  24. Suchman A.L., Mushlin A.I. How well does the activated partial thromboplastin time predict postoperative hemorrhage? JAMA. 1986; 256(6): 750–3.
  25. Narr B.J., Warner M.E., Schroeder D.R., Warner M.A. Outcomes of patients with no laboratory assessment before anesthesia and a surgical procedure. Mayo Clin Proc. 1997; 72(6): 505–9.
  26. Григорьев Е.В., Лебединский К.М., Щеголев А.В. и др. Реанимация и интенсивная терапия при острой массивной кровопотере у взрослых пациентов. Анестезиология и реаниматология. 2020; 1: 5–24. DOI: 10.17116/anaesthesiology20200115 [Grigor'ev E.V., Lebedinskii K.M., Schegolev A.V., et al. Resuscitation and intensive care in acute massive blood loss in adults (clinical guidelines). Russian Journal of Anesthesiology and Reanimatology. 2020; 1: 5–24. DOI: 10.17116/anaesthesiology20200115 (In Russ)]
  27. Синьков С.В., Заболотских И.Б. Диагностика и коррекция расстройств системы гемостаза. 2-е издание, переработанное и дополненное. Москва, 2017. 335 с. ISBN 978-5-98811-457-4 [Sinkov S.V., Zabolotskikh I.B. Diagnosis and correction of disorders of the hemostatic system. 2nd edition. Moscow, 2017. 335 pp. ISBN 978-5-98811-457-4 (In Russ)]
  28. Amgalan A., Allen T., Othman M., et al. Systematic review of viscoelastic testing (TEG/ROTEM) in obstetrics and recommendations from the women's SSC of the ISTH. J Thromb Haemost. 2020; 18(8): 1813–38. http://DOI: 10.1111/jth.14882
  29. de Lange N.M., van Rheenen-Flach L.E., Lancé M.D., et al. Peri-partum reference ranges for ROTEM(R) thromboelastometry. Br J Anaesth. 2014; 112(5): 852–9. DOI: 10.1093/bja/aet480
  30. Bugaev N., Como J.J., Golani G., et al. Thromboelastography and rotational thromboelastometry in bleeding patients with coagulopathy: Practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2020; 89(6): 999–1017. DOI: 10.1097/TA.0000000000002944
  31. Ramler P.I., Gillissen A., Henriquez D.D.C.A., et al. Clinical value of early viscoelastometric point-of-care testing during postpartum hemorrhage for the prediction of severity of bleeding: A multicenter prospective cohort study in the Netherlands. Acta Obstet Gynecol Scand. 2021; 100(9): 1656–64. DOI: 10.1111/aogs.14172
  32. Shamshirsaz A.A., Fox K.A., Erfani H., et al. Trimester-specific thromboelastic values and coagulation activation markers in pregnancy compared across trimesters and compared to the nonpregnant state. Int J Lab Hematol. 2021; 43(5): 1216–24. DOI: 10.1111/ijlh.13472
  33. Tanaka K.A., Henderson R.A., Strauss E.R. Evolution of viscoelastic coagulation testing. Expert Rev Hematol. 2020; 13(7): 697–707. DOI: 10.1080/17474086.2020.1758929
  34. Fahrendorff M., Oliveri R.S., Johansson P.I. The use of viscoelastic haemostatic assays in goal-directing treatment with allogeneic blood products - A systematic review and meta-analysis. Scand J Trauma Resusc Emerg Med. 2017; 25(1): 39. DOI: 10.1186/s13049-017-0378-9
  35. Роненсон А.М., Шифман Е.М., Куликов А.В. и др. Референсные показатели ротационной тромбоэластометрии у беременных и рожениц: систематический обзор и метаанализ. Анестезиология и реаниматология. 2021; 3: 28–40. DOI: 10.17116/anaesthesiology202103128 [Ronenson A.M., Shifman E.M., Kulikov A.V., et al. Reference values of rotational thromboelastometry in pregnancy and parturition: a systematic review and meta-analysis. Russian Journal of Anesthesiology and Reanimatology. 2021; 3: 28–40. DOI: 10.17116/anaesthesiology202103128 (In Russ)]
  36. Shenoy A., Louissaint J., Shannon C., et al. Viscoelastic Testing Prior to Non-surgical Procedures Reduces Blood Product Use Without Increasing Bleeding Risk in Cirrhosis. Dig Dis Sci. 2022; 67(11): 5290–9. DOI: 10.1007/s10620-021-07376-6
  37. Mpaili E., Tsilimigras D.I., Moris D., et al. Utility of viscoelastic coagulation testing in liver surgery: a systematic review. HPB (Oxford). 2021; 23(3): 331–43. DOI: 10.1016/j.hpb.2020.10.023
  38. Weber C.F., Görlinger K., Meininger D., et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology. 2012; 117(3): 531–47. DOI: 10.1097/ALN.0b013e318264c644
  39. Karkouti K., McCluskey S.A., Callum J., et al. Evaluation of a novel transfusion algorithm employing point-of-care coagulation assays in cardiac surgery: a retrospective cohort study with interrupted time-series analysis. Anesthesiology. 2015; 122(3): 560–70. DOI: 10.1097/ALN.0000000000000556
  40. Girdauskas E., Kempfert J., Kuntze T., et al. Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial. J Thorac Cardiovasc Surg. 2010; 140(5): 1117–24.e2. DOI: 10.1016/j.jtcvs.2010.04.043
  41. Буланов А.Ю. Тромбоэластография в современной клинической практике: атлас ТЭГ. М.: Ньюдиамед, 2015. 114 с. ISBN: 978-5-88107-101-1 [Bulanov A. Yu. Thromboelastography in modern clinical practice: TEG atlas. Moscow: Newdiamed, 2015. - 114 p. ISBN:978-5-88107-101-1 (In Russ)]
  42. da Luz L.T., Nascimento B., Rizoli S. Thrombelastography (TEG®): practical considerations on its clinical use in trauma resuscitation. Scand J Trauma Resusc Emerg Med. 2013; 21: 29. DOI: 10.1186/1757-7241-21-29
  43. Trzebicki J., Flakiewicz E., Kosieradzki M., et al. The use of thromboelastometry in the assessment of hemostasis during orthotopic liver transplantation reduces the demand for blood products. Ann Transplant. 2010; 15(3): 19–24.
  44. Walker C., Ingram M., Edwards D., Wood P. Use of thromboelastometry in the assessment of coagulation before epidural insertion after massive transfusion. Anaesthesia. 2011; 66(1): 52–5. DOI: 10.1111/j.1365-2044.2010.06500.x
  45. Doran C.M., Woolley T., Midwinter M.J. Feasibility of using rotational thromboelastometry to assess coagulation status of combat casualties in a deployed setting. J Trauma. 2010; 69 Suppl 1: S40–S48. DOI: 10.1097/TA.0b013e3181e4257b
  46. Lee S.H., Lee S.M., Kim C.S., et al. Use of fibrin-based thromboelastometry for cryoprecipitate transfusion in cardiac surgery involving deep hypothermic circulatory arrest during cardiopulmonary bypass. Blood Coagul Fibrinolysis. 2010; 21(7): 687–91. DOI: 10.1097/MBC.0b013e32833e4228
  47. Остапченко Д.А., Гутников А.И., Давыдова Л.А. Современные подходы к терапии травматического шока (обзор). Общая реаниматология. 2021; 17 (4): 65–76. DOI: 10.15360/1813-9779-2021-4-65-76 [Ostapchenko D.A., Gutnikov A.I., Davydova L.A. Current Approaches to the Treatment of Traumatic Shock (Review). General Reanimatology. 2021; 17(4): 65–76. DOI: 10.15360/1813-9779-2021-4-65-76 (In Russ)]
  48. Baksaas-Aasen K., Gall L.S., Stensballe J., et al. Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial. Intensive Care Med. 2021; 47(1): 49–59. DOI: 10.1007/s00134-020-06266-1
  49. Синьков С.В., Заболотских И.Б. Алгоритм дифференциальной диагностики периоперационных нарушений гемостаза. Тромбоз, гемостаз и реология. 2016; 67(S3): 381–2. [Sinkov S.V., Zabolotskikh I.B. Algorithm for differential diagnosis of perioperative hemostasis disorders. Thrombosis, hemostasis and rheology. 2016; 67(S3): 381–2. (In Russ)]
  50. Синьков С.В., Заболотских И.Б., Шапошников С.А. Приобретенные коагулопатии: современные подходы к дифференциальной диагностике и интенсивной терапии с позиций доказательной медицины. Общая реаниматология. 2007; 3(6): 192–8. DOI: 10.15360/1813-9779-2007-6-192-198 [Sinkov S.V., Zabolotskikh I.B., Shaposhnikov S.A. Acquired Coagulopathies: Current Approaches to Differential Diagnosis and Intensive Care in the Context of Evidence-Based Medicine. General Reanimatology. 2007; 3(6): 192–8. DOI: 10.15360/1813-9779-2007-6-192-198 (In Russ)]
  51. Wada H., Thachil J., Di Nisio M., et al. Harmonized guidance for disseminated intravascular coagulation from the International Society on Thrombosis and Haemostasis and the current status of anticoagulant therapy in Japan: a rebuttal. J Thromb Haemost. 2013; 11(11): 2078–9. DOI: 10.1111/jth.12366
  52. Тромбоз и гемостаз. Шкалы и алгоритмы (пособие под ред. Ройтмана Е.В. и Левшина Н.Ю.). М:2016. 62 с. [Thrombosis and hemostasis. Scales and algorithms. Eds. Roitman E.V., Levshin N.Yu. Moscow: 2016. 62 p. (In Russ)]
  53. Заболотских И.Б., Синьков С.В., Аверьянова Л.Е. Синдром диссеминированного внутрисосудистого свертывания крови: диагностика и интенсивная терапия. Анестезиология и реаниматология. 2007; 2: 71–75. [Zabolotskikh I.B., Sinkov S.V., Averyanova L.E. Sindrom disseminirovannogo vnutrisosudistogo svertyvaniya krovi: diagnostika i intensivnaya terapiya. Anesthesiology and Reanimatology. 2007; 2: 71–75. (In Russ)]
  54. Роненсон А.М., Распопин Ю.С., Шифман Е.М. и др. Эффективность ротационной тромбоэластометрии для диагностики и коррекции коагулопатии при массивном послеродовом кровотечении: когортное ретроспективное многоцентровое исследование «ДиПТЭМ». Вестник интенсивной терапии имени А.И. Салтанова. 2023; 1: 34–42. DOI: 10.21320/1818-474X-2023-1-34-42. [Ronenson A.M., Raspopin Y.S., Shifman E.M., et al. Efficacy of rotational thromboelastometry for diagnosis and correction of coagulopathy in massive postpartum hemorrhage: a cohort retrospective multi-center DiPTEM study. Annals of Critical Care. 2023; 1: 34–42. DOI: 10.21320/1818-474X-2023-1-34-42. (In Russ)]
  55. Синьков С.В., Жилин И.В., Заболотских И.Б. Прогнозирование различных форм послеоперационной острой печеночной недостаточности. Анестезиология и реаниматология. 2017; 62(1): 73–6. [Sinkov S.V., Zhilin I.V., Zabolotskikh I.B. Prediction of various forms of postoperative acute liver failure. Anesthesiology and Reanimatology. 2017;62(1): 73–6. (In Russ)]
  56. Синьков С.В. Характер нарушений системы гемостаза у пациентов с хронической печеночной недостаточностью. Вестник хирургической гастроэнтерологии. 2017; 2: 23–7. [Sinkov S.V. The nature of disorders of the hemostatic system in patients with chronic liver failure. Bulletin of surgical gastroenterology. 2017; 2: 23–7. (In Russ)]
  57. Lange N.W., Salerno D.M., Berger K., et al. Management of Hepatic Coagulopathy in Bleeding and Nonbleeding Patients: An Evidence-Based Review. J Intensive Care Med. 2021; 36(5): 524–41. DOI: 10.1177/0885066620903027
  58. Stravitz R.T., Lisman T., Luketic V.A., et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol. 2012; 56(1): 129–36. DOI: 10.1016/j.jhep.2011.04.020
  59. Agarwal B., Wright G., Gatt A., et al. Evaluation of coagulation abnormalities in acute liver failure. J Hepatol. 2012; 57(4): 780–6. DOI: 10.1016/j.jhep.2012.06.020
  60. Заболотских И.Б., Киров М.Ю., Афончиков В.С. и др. Периоперационное ведение пациентов, получающих длительную антитромботическую терапию. Методические рекомендации Общероссийской общественной организации «Федерация анестезиологов и реаниматологов». Вестник интенсивной терапии имени А.И. Салтанова. 2021; 3: 7–26. DOI: 10.21320/1818-474X-2021-3-7-26.[Zabolotskikh I.B., Kirov M.Y., Afonchikov V.S., et al. Perioperative management of patients receiving long-term antithrombotic therapy. Clinical practice recommendations of the national “Federation of Anesthesiologists and Reanimatologists”. Annals of Critical Care. 2021; 3: 7–26. DOI: 10.21320/1818-474X-2021-3-7-26 (In Russ)]
  61. Consunji R., Elseed A., El-Menyar A., et al. The effect of massive transfusion protocol implementation on the survival of trauma patients: a systematic review and meta-analysis. Blood Transfus. 2020; 18(6): 434–45. DOI: 10.2450/2020.0065-20
  62. Sommer N., Schnüriger B., Candinas D., et al. Massive transfusion protocols in nontrauma patients: A systematic review and meta-analysis. J Trauma Acute Care Surg. 2019; 86(3): 493–504. DOI: 10.1097/TA.0000000000002101
  63. Mitra B., O'Reilly G., Cameron P.A., et al. Effectiveness of massive transfusion protocols on mortality in trauma: a systematic review and meta-analysis. ANZ J Surg. 2013; 83(12): 918–23. DOI: 10.1111/ans.12417
  64. Bhangu A., Nepogodiev D., Doughty H., et al. Meta-analysis of plasma to red blood cell ratios and mortality in massive blood transfusions for trauma. Injury. 2013; 44(12): 1693–9. DOI: 10.1016/j.injury.2012.07.193
  65. Enticott J.C., Jeffcott S., Ibrahim J.E., et al. A review on decision support for massive transfusion: understanding human factors to support the implementation of complex interventions in trauma. Transfusion. 2012; 52(12): 2692–705. DOI: 10.1111/j.1537-2995.2012.03648.x
  66. Lier H., Böttiger B.W., Hinkelbein J., et al. Coagulation management in multiple trauma: a systematic review. Intensive Care Med. 2011; 37(4): 572–82. DOI: 10.1007/s00134-011-2139-y
  67. Wada H., Asakura H., Okamoto K., et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010; 125(1): 6–11. DOI: 10.1016/j.thromres.2009.08.017
  68. Wada H., Thachil J., Di Nisio M., et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013; 10.1111/jth.12155. DOI: 10.1111/jth.12155
  69. Kawasugi K., Wada H., Hatada T., et al. Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases. Thromb Res. 2011; 128(2): 186–90. DOI: 10.1016/j.thromres.2011.02.015
  70. Заболотских И.Б., Синьков С.В., Шапошников С.А. Выбор антикоагулянта в зависимости от стадии ДВС-синдрома. Анестезиология и реаниматология. 2004; 3: 29–31. [Zabolotskikh I.B., Sinkov S.V., Shaposhnikov S.A. The choice of anticoagulant depending on the stage of DIC syndrome. Anesteziologiya i reanimatologiya. 2004; 3: 29–31. (In Russ)]
  71. Cao Z., Li Q., Guo J., et al. Optimal administration strategies of tranexamic acid to minimize blood loss during spinal surgery: results of a Bayesian network meta-analysis. Ann Med. 2022; 54(1): 2053–63. DOI: 10.1080/07853890.2022.2101687
  72. Tran Q.K., Tang K., Pourmand A. Tranexamic acid and Gastrointestinal bleed: Effect of the HALT-IT trial on current meta-analysis. Am J Emerg Med. 2022; 59: 165–7. DOI: 10.1016/j.ajem.2022.06.050
  73. Fowler H., Law J., Tham S.M., et al. Impact on blood loss and transfusion rates following administration of tranexamic acid in major oncological abdominal and pelvic surgery: A systematic review and meta-analysis. J Surg Oncol. 2022; 126(3): 609–21. DOI: 10.1002/jso.26900
  74. Ageron F.X., Shakur-Still H., Roberts I. Effects of tranexamic acid treatment in severely and non-severely injured trauma patients. Transfusion. 2022; 62 Suppl 1(Suppl 1): S151–S157. DOI: 10.1111/trf.16954
  75. Laikhter E., Comer C.D., Shiah E., et al. A Systematic Review and Meta-Analysis Evaluating the Impact of Tranexamic Acid Administration in Aesthetic Plastic Surgery. Aesthet Surg J. 2022; 42(5): 548–58. DOI: 10.1093/asj/sjab333
  76. Koh A., Adiamah A., Gomez D., et al. Safety and Efficacy of Tranexamic Acid to Minimise Perioperative Bleeding in Hepatic Surgery: A Systematic Review and Meta-Analysis. World J Surg. 2022; 46(2): 441–9. DOI: 10.1007/s00268-021-06355-2
  77. Heyns M., Knight P., Steve A.K., et al. A Single Preoperative Dose of Tranexamic Acid Reduces Perioperative Blood Loss: A Meta-analysis. Ann Surg. 2021; 273(1): 75–81. DOI: 10.1097/SLA.0000000000003793
  78. Mannucci P.M., Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007; 356(22): 2301–11. DOI: 10.1056/NEJMra067742
  79. Gando S., Wada H., Thachil J. Scientific and Standardization Committee on DIC of the International Society on Thrombosis and Haemostasis (ISTH). Differentiating disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype from coagulopathy of trauma and acute coagulopathy of trauma-shock (COT/ACOTS). J Thromb Haemost. 2013; 11(5): 826–35. DOI: 10.1111/jth.12190
  80. Di Nisio M., Baudo F., Cosmi B., et al. Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res. 2012; 129(5): e177–e184. DOI: 10.1016/j.thromres.2011.08.028
  81. Куликов А.В., Шифман Е.М., Проценко Д.Н. и др. Диагностика и интенсивная терапия синдрома диссеминированного внутрисосудистого свертывания крови при массивной кровопотере в акушерстве (методические рекомендации). Анестезиология и реаниматология. 2022; 2: 5–23. DOI: 10.17116/anaesthesiology20220215 [Kulikov A.V., Shifman E.M., Protsenko D.N., et al. Diagnosis and intensive therapy of disseminated intravascular coagulation syndrome in massive blood loss in obstetrics (guidelines). Russian Journal of Anesthesiology and Reanimatology. 2022; 2: 5–23. (In Russ)]
  82. Pernerstorfer T., Hollenstein U., Hansen J., et al. Heparin blunts endotoxin-induced coagulation activation. Circulation. 1999; 100(25): 2485–90. DOI: 10.1161/01.cir.100.25.2485
  83. Warren B.L., Eid A., Singer P., et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial [published correction appears in JAMA 2002; 287(2): 192]. JAMA. 2001; 286(15): 1869–78. DOI: 10.1001/jama.286.15.1869
  84. Aoki N., Matsuda T., Saito H., et al. A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. Int J Hematol. 2002; 75(5): 540–7. DOI: 10.1007/BF02982120
  85. Saito H., Maruyama I., Shimazaki S., et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007; 5(1): 31–41. DOI: 10.1111/j.1538-7836.2006.02267.x
  86. Youssef W.I., Salazar F., Dasarathy S., et al. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol. 2003; 98(6): 1391–4. DOI: 10.1111/j.1572-0241.2003.07467.x
  87. Stravitz R.T., Kramer A.H., Davern T., et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med. 2007; 35(11): 2498–508. DOI: 10.1097/01.CCM.0000287592.94554.5F
  88. Pereira S.P., Langley P.G., Williams R. The management of abnormalities of hemostasis in acute liver failure. Semin Liver Dis. 1996; 16(4): 403–14. DOI: 10.1055/s-2007-1007253
  89. Chowdary P., Saayman A.G., Paulus U., et al. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol. 2004; 125(1): 69–73. DOI: 10.1111/j.1365-2141.2004.04868.x
  90. Giannini E.G., Greco A., Marenco S., et al. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol. 2010; 8(10): 899–e109. DOI: 10.1016/j.cgh.2010.06.018
  91. Segal J.B., Dzik W.H. Transfusion Medicine/Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion. 2005; 45(9): 1413–25. DOI: 10.1111/j.1537-2995.2005.00546.x
  92. O'Shaughnessy D.F., Atterbury C., Bolton Maggs P., et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004; 126(1): 11–28. DOI: 10.1111/j.1365-2141.2004.04972.x
  93. Lorenz R., Kienast J., Otto U., et al. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol. 2003; 15(1): 15–20. DOI: 10.1097/00042737-200301000-00004
  94. Kuroda S., Kobayashi T., Tashiro H., et al. A multicenter randomized controlled trial comparing administration of antithrombin III after liver resection (HiSCO-05 trial). Surgery. 2021; 170(4): 1140–50. DOI: 10.1016/j.surg.2021.03.057
  95. Porte R.J., Molenaar I.Q., Begliomini B., et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomized double-blind study. EMSALT Study Group. Lancet. 2000; 355(9212): 1303–9.
  96. Boylan J.F., Klinck J.R., Sandler A.N., et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology. 1996; 85(5): 1043–8.
  97. Hendriks H.G., Meijer K., de Wolf J.T., et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation. 2001; 71(3): 402–5. DOI: 10.1097/00007890-200102150-00011
  98. Lodge J.P., Jonas S., Jones R.M., et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl. 2005; 11(8): 973–9. DOI: 10.1002/lt.20470
  99. Planinsic R., van der Meer J., Testa G., et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl. 2005; 11(8): 895–900. DOI: 10.1002/lt.20458
  100. Hedges S.J., Dehoney S.B., Hooper J.S., et al. Evidencebased treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 2007; 3: 138–53. DOI: 10.1038/ncpneph0421
  101. Manno C., Bonifati C., Torres D.D., et al. Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. Am J Kidney Dis. 2011; 57: 850–5. DOI: 10.1053/j.ajkd.2010.12.019
  102. Vigano G., Gaspari F., Locatelli M., et al. Doseeffect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney Int. 1988; 34: 853–8. DOI: 10.1038/ki.1988.260
  103. Holcomb J.B., Jenkins D., Rhee P., et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma. 2007; 62(2): 307–10. DOI: 10.1097/TA.0b013e3180324124
  104. Dente C.J., Shaz B.H., Nicholas J.M., et al. Improvements in early mortality and coagulopathy are sustained better in patients with blunt trauma after institution of a massive transfusion protocol in a civilian level I trauma center. J Trauma. 2009; 66(6): 1616–24. DOI: 10.1097/TA.0b013e3181a59ad5
  105. Bulger E.M., May S., Brasel K.J., et al. Out-of-hospital hypertonic resuscitation following severe traumatic brain injury: a randomized controlled trial. JAMA. 2010; 304(13): 1455–64. DOI: 10.1001/jama.2010.1405
  106. Ketchum L., Hess J.R., Hiippala S. Indications for early fresh frozen plasma, cryoprecipitate, and platelet transfusion in trauma. J Trauma. 2006; 60(6 Suppl): S51– S58. DOI: 10.1097/01.ta.0000199432.88847.0c
  107. Holcomb J.B., Hess J.R. Early massive trauma transfusion: state of the art: editor’s introduction. J Trauma Acute Care Surg. 2006; 60(6): S1–2.
  108. Holcomb J.B., Tilley B.C., Baraniuk S., et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015; 313(5): 471–82. DOI: 10.1001/jama.2015.12
  109. Baraniuk S., Tilley B.C., del Junco D.J., et al. Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: design, rationale and implementation. Injury. 2014; 45(9): 1287–95. DOI: 10.1016/j.injury.2014.06.001
  110. Toy P., Popovsky M.A., Abraham E., et al. Transfusion-related acute lung injury: definition and review. Crit Care Med. 2005; 33(4): 721–6. DOI: 10.1097/01.ccm.0000159849.94750.51
  111. Holness L., Knippen M.A., Simmons L., et al. Fatalities caused by TRALI. Transfus Med Rev. 2004; 18(3): 184–8. DOI: 10.1016/j.tmrv.2004.03.004
  112. Jost D., Lemoine S., Lemoine F., et al. Prehospital Lyophilized Plasma Transfusion for Trauma-Induced Coagulopathy in Patients at Risk for Hemorrhagic Shock: A Randomized Clinical Trial. JAMA Netw Open. 2022; 5(7): e2223619. DOI: 10.1001/jamanetworkopen.2022.23619
  113. Kao T.W., Lee Y.C., Chang H.T. Prothrombin Complex Concentrate for Trauma Induced Coagulopathy: A Systematic Review and Meta-Analysis. J Acute Med. 2021; 11(3): 81–9. DOI: 10.6705/j.jacme.202109_11(3).0001
  114. CRASH-2 Trial Collaborators, Shakur H, Roberts I, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo controlled trial. Lancet. 2010; 376: 23e32. DOI: 10.1016/S0140-6736(10)60835-5
  115. Biffi A., Porcu G., Castellini G., et al. Systemic hemostatic agents initiated in trauma patients in the pre-hospital setting: a systematic review. Eur J Trauma Emerg Surg. 2023; 49(3): 1259–70. DOI: 10.1007/s00068-022-02185-6
  116. Al-Jeabory M., Szarpak L., Attila K., et al. Efficacy and Safety of Tranexamic Acid in Emergency Trauma: A Systematic Review and Meta-Analysis. J Clin Med. 2021; 10(5): 1030. DOI: 10.3390/jcm10051030
  117. Roberts I., Shakur H., Afolabi A. et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011; 377(9771): 1096–101.1101e1091–1092. DOI: 10.1016/S0140-6736(11)60278-X
  118. July J., Pranata R. Tranexamic acid is associated with reduced mortality, hemorrhagic expansion, and vascular occlusive events in traumatic brain injury - meta-analysis of randomized controlled trials. BMC Neurol. 2020; 20(1): 119. DOI: 10.1186/s12883-020-01694-4
  119. Coburn W., Trottier Z., Villarreal R.I., et al. Prehospital Pharmacotherapy in Moderate and Severe Traumatic Brain Injury: A Systematic Review. Med J (Ft Sam Houst Tex). 2023; (Per 23-1/2/3): 47–56.
  120. Huang H., Xin M., Wu X., et al. The efficacy of tranexamic acid treatment with different time and doses for traumatic brain injury: a systematic review and meta-analysis. Thromb J. 2022; 20(1): 79. DOI: 10.1186/s12959-022-00440-9
  121. Devereaux P.J., Marcucci M., Painter T.W., et al. Tranexamic Acid in Patients Undergoing Noncardiac Surgery. N Engl J Med. 2022; 386(21): 1986–97. DOI: 10.1056/NEJMoa2201171
  122. Roberts I., Shakur H., Ker K., et al. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2012; 12: CD004896.
  123. Roberts I., Prieto-Merino D., Manno D. Mechanism of action of tranexamic acid in bleeding trauma patients: an exploratory analysis of data from the CRASH-2 trial. Crit Care. 2014; 18(6): 685. DOI: 10.1186/s13054-014-0685-8
  124. Roberts I., Perel P., Prieto-Merino D., et al. Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial. BMJ. 2012; 345: e5839.
  125. Kozek-Langenecker S.A., Ahmed A.B., Afshari A. et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2017; 34: 332–95. DOI: 10.1097/EJA.0000000000000630
  126. Артымук Н.В., Астахов А.А., Белокриницкая Т.Е. и др. Интенсивная терапия синдрома диссеминированного внутрисосудистого свертывания крови (ДВС-синдром, коагулопатия) в акушерстве. Анестезиология и реаниматология. 2019; 2: 5–26. DOI: 10.17116/anaesthesiology20190215 [Artymuk N.V., Astahov A.A., Belokrinitskaia T.E., et al. Intensive care for disseminated intravascular coagulation syndrome (DIC-syndrome, coagulopathy) in obstetrics. Russian Journal of Anesthesiology and Reanimatology. 2019; 2: 5–26. (In Russ)]
  127. Gayet-Ageron A., Prieto-Merino D., Ker K. et al. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40138 bleeding patients. Lancet. 2018; 391(10116): 125–32. DOI: 10.1016/S0140-6736(17)32455-8
  128. Schöchl H., Nienaber U., Hofer G. et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEMW)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care. 2010; 14: R55. DOI: 10.1186/cc8948
  129. Shaz B.H., Dente C.J., Nicholas J. et al. Increased number of coagulation products in relationship to red blood cell products transfused improves mortality in trauma patients. Transfusion. 2010; 50(2): 493–500. DOI: 10.1111/j.1537-2995.2009.02414.x
  130. Morrow G.B., Feller T., McQuilten Z., et al. Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial. Crit Care. 2022; 26(1): 290. DOI: 10.1186/s13054-022-04167-x
  131. Hiippala S.T., Myllyla G.J., Vahtera E.M. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg. 1995; 81(2): 360–5.
  132. Schöchl H., Cotton B., Inaba K., et al. FIBTEM provides early prediction of massive transfusion in trauma. Crit Care. 2011; 15(6): R265. DOI: 10.1186/cc10539
  133. Stinger H.K., Spinella P.C., Perkins J.G., et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. Journal of Trauma. 2008; 64(2 Suppl): S79–85. DOI: 10.1097/TA.0b013e318160a57b
  134. Schöchl H., Nienaber U., Maegele M. et al. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care. 2011; 15(2): R83. DOI: 10.1186/cc10078
  135. Nardi G., Agostini V., Rondinelli B. et al. Traumainduced coagulopathy: impact of the early coagulation support protocol on blood product consumption, mortality and costs. Crit Care. 2015; 19(1): 83. DOI: 10.1186/s13054-015-0817-9
  136. Ziegler B., Bachler M., Haberfellner H., et al. Efficacy of prehospital administration of fibrinogen concentrate in trauma patients bleeding or presumed to bleed (FIinTIC): A multicentre, double-blind, placebo-controlled, randomised pilot study. Eur J Anaesthesiol. 2021; 38(4): 348–57. DOI: 10.1097/EJA.0000000000001366
  137. Stansbury L.G., Hess A.S., Thompson K., et al. The clinical significance of platelet counts in the first 24 hours after severe injury. Transfusion. 2013; 53(4): 783–9. DOI: 10.1111/j.1537-2995.2012.03828.x
  138. Joseph B., Aziz H., Zangbar B., et al. Acquired coagulopathy of traumatic brain injury defined by routine laboratory tests: which laboratory values matter? J Trauma Acute Care Surg. 2014; 76(1): 121–5. DOI: 10.1097/TA.0b013e3182a9cc95
  139. Kashuk J.L., Moore E.E., Johnson J.L., et al. Postinjury life threatening coagulopathy: is 1:1 fresh frozen plasma:packed red blood cells the answer? Journal of Trauma. 2008; 65(2): 261–70. DOI: 10.1097/TA.0b013e31817de3e1
  140. Nekludov M., Bellander B.M., Blomback M., et al. Platelet dysfunction in patients with severe traumatic brain injury. J Neurotrauma. 2007; 24(11): 1699–706. DOI: 10.1089/neu.2007.0322
  141. Wohlauer M.V., Moore E.E., Thomas S., et al. Early platelet dysfunction: an unrecognized role in the acute coagulopathy of trauma. J Am Coll Surg. 2012; 214(5): 739–46. DOI: 10.1016/j.jamcollsurg.2012.01.050
  142. Counts R.B., Haisch C., Simon T.L., et al. Hemostasis in massively transfused trauma patients. Ann Surg. 1979; 190(1): 91–9. DOI: 10.1097/00000658-197907000-00020
  143. Ciavarella D., Reed R.L., Counts R.B., et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol. 1987; 67(3): 365–8. DOI: 10.1111/j.1365-2141.1987.tb02359.x
  144. Johansson P.I., Stensballe J., Rosenberg I., et al. Proactive administration of platelets and plasma for patients with a ruptured abdominal aortic aneurysm: evaluating a change in transfusion practice. Transfusion. 2007; 47(4): 593–8. DOI: 10.1111/j.1537-2995.2007.01160.x
  145. Holcomb J.B., Wade C.E., Michalek J.E., et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg. 2008; 248(3): 447–58.
  146. Zink K.A., Sambasivan C.N., Holcomb J.B., et al. A high ratio of plasma and platelets to packed red blood cells in the first 6 hours of massive transfusion improves outcomes in a large multicenter study. Am J Surg. 2009; 197(5): 565–70.
  147. McQuilten Z.K., Crighton G., Engelbrecht et al. Transfusion interventions in critical bleeding requiring massive transfusion: a systematic review. Transfus Med Rev. 2015; 29(2): 127–37.
  148. Quinlan D.J., Eikelboom J.W., Weitz J.I. Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding. Circulation. 2013; 128(11): 1179–81.
  149. Dezee K.J., Shimeall W.T., Douglas K.M. et al. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta analysis. Arch Intern Med. 2006; 166(4): 391–7.
  150. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124(14): 1573–9.
  151. Marlu R., Hodaj E., Paris A., et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012; 108(2): 217–24. DOI: 10.1160/TH12-03-0179.
  152. Goldstein J.N., Refaai M.A., Milling Jr T.J., et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015; 385(9982): 2077–87. DOI: 10.1016/S0140-6736(14)61685-8
  153. Huttner H.B., Schellinger P.D., Hartmann M. et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006; 37(6): 1465–70. DOI: 10.1161/01.STR.0000221786.81354.d6
  154. Edavettal M., Rogers A., Rogers F., et al. Prothrombin complex concentrate accelerates international normalized ratio reversal and diminishes the extension of intracranial hemorrhage in geriatric trauma patients. Am Surg. 2014; 80(4): 372–6.
  155. Baglin T.P., Keeling D.M., Watson H.G. Guidelines on oral anticoagulation (warfarin): third edition–2005 update. Br J Haematol. 2006; 132(3): 277–85. DOI: 10.1111/j.1365-2141.2005.05856.x
  156. Clave A., Fazilleau F., Dumser D., et al. Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: a case-control study in 70 patients. Orthop Traumatol Surg Res. 2012; 98(5): 484–90. DOI: 10.1016/j.otsr.2011.12.005
  157. Hosseini S.F., Behnam-Roudsari S., Alavinia G., et al. Diagnostic and prognostic value of Sepsis-Induced coagulopathy and International Society on Thrombosis and Hemostasis scoring systems in COVID-19-associated disseminated intravascular coagulopathy. J Res Med Sci. 2021; 26: 102. DOI: 10.4103/jrms.JRMS_1295_20
  158. Lee D.H., Lee B.K., Jeung K.W., et al. Performance of 5 disseminated intravascular coagulation score systems in predicting mortality in patients with severe trauma. Medicine (Baltimore). 2018; 97(33): e11912. DOI: 10.1097/MD.0000000000011912
  159. Asakura H., Takahashi H., Uchiyama T., et al. DIC subcommittee of the Japanese Society on Thrombosis and Hemostasis. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2016; 14: 42. DOI: 10.1186/s12959-016-0117-x
  160. Thrombosis and Hemostasis group, Hematology Society, Chinese Medical Association. [Consensus of Chinese experts on diagnosis and treatment of disseminated intravascular coagulation (version 2012)]. Zhonghua Xue Ye Xue Za Zhi. 2012; 33(11): 978–9.
  161. Saito S., Uchino S., Hayakawa M., et al. Japan Septic Disseminated Intravascular Coagulation (JSEPTIC DIC) study group. Epidemiology of disseminated intravascular coagulation in sepsis and validation of scoring systems. J Crit Care. 2019; 50: 23–30. DOI: 10.1016/j.jcrc.2018.11.009
  162. Frank C.S., Larsen J.B. Prognostic Impact of the International Society on Thrombosis and Hemostasis Disseminated Intravascular Coagulation Score in Sepsis: A Systematic Review. Semin Thromb Hemost. 2023. DOI: 10.1055/s-0043-1761216
  163. Iba T., Connors J.M., Nagaoka I., et al. Recent advances in the research and management of sepsis-associated DIC. Int J Hematol. 2021; 113(1): 24–33. DOI: 10.1007/s12185-020-03053-y
  164. Iba T., Levi M., Thachil J., et al. Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis on sepsis-induced coagulopathy in the management of sepsis. J Thromb Haemost. 2023; 21(1): 145–53. DOI: 10.1016/j.jtha.2022.10.022
  165. Kudo D., Goto T., Uchimido R., et al. Coagulation phenotypes in sepsis and effects of recombinant human thrombomodulin: an analysis of three multicentre observational studies. Crit Care. 2021; 25(1): 114. DOI: 10.1186/s13054-021-03541-5
  166. Lippi G., Henry B.M., Sanchis-Gomar F. Plasma Antithrombin Values Are Significantly Decreased in Coronavirus Disease 2019 (COVID-19) Patients with Severe Illness. Semin Thromb Hemost. 2021; 47(4): 460–2. DOI: 10.1055/s-0040-1716873
  167. Wiedermann C.J. Antithrombin concentrate use in disseminated intravascular coagulation of sepsis: meta-analyses revisited. J Thromb Haemost. 2018; 16(3): 455–7. DOI: 10.1111/jth.13950
  168. Allingstrup M., Wetterslev J., Ravn F.B., et al. Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2016; 42(4): 505–20. DOI: 10.1007/s00134-016-4225-7
  169. Czempik P.F., Wiórek A. Management Strategies in Septic Coagulopathy: A Review of the Current Literature. Healthcare (Basel). 2023; 11(2): 227. DOI: 10.3390/healthcare11020227
  170. Catenacci V., Sheikh F., Patel K., et al. The prognostic utility of protein C as a biomarker for adult sepsis: a systematic review and meta-analysis. Crit Care. 2022; 26(1): 21. DOI: 10.1186/s13054-022-03889-2
  171. Boscolo A., Spiezia L., De Cassai A., et al. Are thromboelastometric and thromboelastographic parameters associated with mortality in septic patients? A systematic review and meta-analysis. J Crit Care. 2021; 61: 5–13. DOI: 10.1016/j.jcrc.2020.09.034
  172. British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. British Journal of Haematology. 2017; 176: 365–94.
  173. Клинические рекомендации по диагностике и лечению атипичного гемолитико-уремического синдрома. Нефрология и диализ. 2015; 17(3): 242–64. [Clinical guidelines for the diagnosis and treatment of atypical hemolytic-uremic syndrome. Nephrologia and dialysis. 2015; 17(3): 242–64 (In Russ)]
  174. Cuker A., Arepally G.M., Chong B.H., et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018; 2(22): 3360–92. DOI: 10.1182/bloodadvances.2018024489
  175. Heparin-Induced Thrombocytopenia (3rd ed.). Eds. Warkentin T., Greinacher A. CRC Press, 2003. DOI: 10.1201/9780824758844
  176. Warkentin T.E., Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 Suppl): 311S-337S. DOI: 10.1378/chest.126.3_suppl.311S
  177. Finazzi G., Marchioli R., Brancaccio V., et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J. Thromb. Haemost. 2005; 3: 848–53. DOI: 10.1111/j.1538-7836.2005.01340.x
  178. Urbanus R.T., Siegerink B., Roest M., et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case–control study. Lancet Neurol. 2009; 8: 998–1005. DOI: 10.1016/S1474-4422(09)70239-X
  179. Asherson R.A., Cervera R., Piette J.C., et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore). 2001; 80: 355–76. DOI: 10.1097/00005792-200111000-00002
  180. Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun. Rev. 2006; 6: 98–103. DOI: 10.1016/j.autrev.2006.06.013
  181. Решетняк Т.М. Лечение антифосфолипидного синдрома: современные стандарты. Тромбоз, гемостазиреология. 2016; 1: 11–20. [Reshetnyak T.M. Treatment of antiphospholipid syndrome: modern standards. Tromboz, gemostaz i reologiya. 2016; 1: 11–20. (In Russ)]
  182. Wu X., Cao S., Yu B., et al. Comparing the efficacy and safety of direct oral anticoagulants versus Vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis. Blood Coagul Fibrinolysis. 2022; 33(7): 389–401. DOI: 10.1097/MBC.0000000000001153
  183. Pastori D., Menichelli D., Cammisotto V., et al. Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines. Front Cardiovasc Med. 2021; 8: 715878. DOI: 10.3389/fcvm.2021.715878
  184. Tektonidou M.G., Andreoli L., Limper M., et al. Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. RMD Open. 2019; 5(1): e000924. DOI: 10.1136/rmdopen-2019-000924
  185. Bala M.M., Paszek E., Lesniak W., et al. Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. Cochrane Database Syst Rev. 2018; 7(7): CD012534. DOI: 10.1002/14651858.CD012534.pub2
  186. Silva F.F., Carvalho J.F. Intensity of anticoagulation in the treatment of thrombosis in the antiphospholipid syndrome: a meta-analysis. Rev Bras Reumatol. 2015; 55(2): 159–66. DOI: 10.1016/j.rbr.2014.08.016
  187. Reynaud Q., Lega J.C., Mismetti P., et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2014; 13(6): 595–608. DOI: 10.1016/j.autrev.2013.11.004
  188. Ruiz-Irastorza G., Hunt B.J., Khamashta M.A. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007; 57(8): 1487–95. DOI: 10.1002/art.23109
  189. Shibuya M., Kimura Y., Takuma S., et al. Cardiovascular Considerations in Anesthetic Management for a Patient With Antiphospholipid Syndrome and Decreased Cardiac Function: A Case Study. Anesth Prog. 2021; 68(1): 33–7. DOI: 10.2344/anpr-67-03-07
  190. Miller's Anesthesia, 2 Volume Set 9th Ed. Ed: Gropper M., Eriksson L., Fleisher L., et al.Elsevier; 2019. 3112 p
  191. Stoelting's anesthesia and co-existing disease, seventh edition. Eds. Hines R.L., Marschall K.E. Elsevier, Inc. 2018. 740 p.
  192. Hermans C., Altisent C., Batorova A., et al. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia. 2009; 15: 639–58. DOI: 10.1111/j.1365-2516.2008.01950.x
  193. Mauser-Bunschoten E.P., Kleine Budde I., Lopaciuk S., et al. An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact (R)), results of phase III and IV clinical studies. Haemophilia. 2011; 17: 439–45. DOI: 10.1111/j.1365-2516.2010.02453.x
  194. Strauss T., Lubetsky A., Ravid B., et al. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study. Haemophilia. 2011; 17: 625–9. DOI: 10.1111/j.1365-2516.2010.02464.x
  195. Pruthi R.K., Mathew P., Valentino L.A., et al. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb Haemost. 2007; 98: 726–32.
  196. Iorio A., Matino D., D’Amico R., et al. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev. 2010; 8: CD004449. DOI: 10.1002/14651858.CD004449.pub3
  197. Hvas A.M., Sorensen H.T., Norengaard L., et al. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost. 2007; 5: 2408–14. DOI: 10.1111/j.1538-7836.2007.02755.x
  198. Togioka B.M., Burwick R.M., Kujovich J.L. Delivery and neuraxial technique outcomes in patients with hemophilia and in hemophilia carriers: a systematic review. J Anesth. 2021; 35(2): 288–302. DOI: 10.1007/s00540-021-02911-1
  199. Choi S., Brull R. Neuraxial techniques in obstetric and non-obstetric patients with common bleeding diatheses. Anesth Analg. 2009; 109(2): 648–60. DOI: 10.1213/ane.0b013e3181ac13d1
  200. Moharrami A., Mafi A.H., Fallah E., et al. Total joint arthroplasty in the patients with haemophilia: General or neuraxial anaesthesia? Haemophilia. 2022; 28(4): e95–e97. DOI: 10.1111/hae.14509
  201. Cesur S., Gürkan Y., Türkyılmaz N., et al. Erişkin hemofili hastasında ultrason rehberliğinde penil blok ile cerrahi anestezi Agri. 2020; 32(3): 162–3. DOI: 10.5505/agri.2018.27676. [Cesur S., Gürkan Y., Türkyılmaz N., et al. Surgical anesthesia using ultrasound-guided penile nerve block for adult hemophilia patient. Agri. 2020 Aug; 32(3): 162–3. DOI: 10.5505/agri.2018.27676 (In Turkish)]
  202. Li S., Qu B., Ma W., et al. Perioperative anaesthesia and coagulation management of haemophilia patients receiving total hip and knee replacement arthroplasty: Experience from a case series. J Orthop Surg (Hong Kong). 2019; 27(3): 2309499019874931. DOI: 10.1177/2309499019874931
  203. Coppola A., Windyga J., Tufano A., et al. Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery. Cochrane Database Syst Rev. 2015;2: CD009961. DOI: 10.1002/14651858.CD009961.pub2
  204. Santagostino E., Escobar M., Ozelo M., et al. Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors. Blood Rev. 2015; 29 (Suppl 1): S9–S18. DOI: 10.1016/S0268-960X(15)30003-5
  205. Tran H.T., Sorensen B., Rea C.J., et al. Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors. Haemophilia. 2014; 20: 369–75. DOI: 10.1111/hae.12318
  206. Howman R., Barnes C., Curtin J., et al. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE(R), in children with von Willebrand disorder: a multi-centre retrospective review. Haemophilia. 2011; 17: 463–9.DOI: 10.1111/j.1365-2516.2010.02445.x
  207. Federici A.B., Barillari G., Zanon E., et al. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand’s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. Haemophilia. 2010; 16: 101–10. DOI: 10.1111/j.1365-2516.2009.02088.x
  208. Federici A.B., Sacco R., Stabile F., et al. Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases. Haemophilia. 2000; 6: 71–7. DOI: 10.1046/j.1365-2516.2000.00370.x
  209. Reale S.C., Farber M.K., Lumbreras-Marquez M.I., et al. Anesthetic Management of Von Willebrand Disease in Pregnancy: A Retrospective Analysis of a Large Case Series. Anesth Analg. 2021; 133(5): 1244–50. DOI: 10.1213/ANE.0000000000005502
  210. Peterson W., Tse B., Martin R., et al. Evaluating hemostatic thresholds for neuraxial anesthesia in adults with hemorrhagic disorders and tendencies: A scoping review. Res Pract Thromb Haemost. 2021; 5(4): e12491. DOI: 10.1002/rth2.12491
  211. Baouahi H., Zerqouni Y., Doumiri M., et al. Le rôle du médecin anesthésiste-réanimateur dans la prise en charge de la femme enceinte porteuse de la maladie de Von Willebrand. Pan Afr Med J. 2015; 22: 335. DOI: 10.11604/pamj.2015.22.335.7997 [Baouahi H., Zerqouni Y., Doumiri M., et al. The role of the anesthesiologist in the care of the pregnant woman with Von Willebrand Disease. Pan Afr Med J. 2015; 22: 335. DOI: 10.11604/pamj.2015.22.335.7997 (In French)]
  212. DiStefano Y.E., Lazar M.D. Successful Ultrasound-Guided Femoral Nerve Blockade and Catheterization in a Patient with Von Willebrand Disease. Case Rep Anesthesiol. 2015; 2015: 106306. DOI: 10.1155/2015/106306
  213. Neff A.T., Sidonio R.F. Jr. Management of VWD. Hematology Am Soc Hematol Educ Program. 2014; 2014: 536–41. DOI: 10.1182/asheducation-2014.1.536
  214. Hauser C.J., Boffard K., Dutton R. et al. Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma. 2010; 69(3): 489–500. DOI: 10.1097/TA.0b013e3181edf36e
  215. Knudson M.M., Cohen M.J., Reidy R. et al. Trauma, transfusions, and use of recombinant factor VIIa: a multicenter case registry report of 380 patients from the Western Trauma Association. J Am Coll Surg. 2011; 212(1): 87–95. DOI: 10.1016/j.jamcollsurg.2010.08.020
  216. Mitra B., Cameron P.A., Parr M.J., et al. Recombinant factor VIIa in trauma patients with the ‘triad of death’. Injury. 2012; 43(9): 1409–14. DOI: 10.1016/j.injury.2011.01.033
  217. Hahn R.G. Adverse effects of crystalloid and colloid fluids. Anaesthesiol Intensive Ther. 2017; 49(4): 303–8. http://DOI: 10.5603/AIT.a2017.0045
  218. Gillissen A., van den Akker T., Caram-Deelder C., et al. Association between fluid management and dilutional coagulopathy in severe postpartum haemorrhage: a nationwide retrospective cohort study. BMC Pregnancy Childbirth. 2018; 18(1): 398. DOI: 10.1186/s12884-018-2021-9
  219. Henriquez D.D.C.A., Bloemenkamp K.W.M., Loeff R.M., et al. Fluid resuscitation during persistent postpartum haemorrhage and maternal outcome: A nationwide cohort study. Eur J Obstet Gynecol Reprod Biol. 2019; 235: 49–56. DOI: 10.1016/j.ejogrb.2019.01.027
  220. Getrajdman C., Sison M., Lin H.M., et al. The impact of crystalloid versus colloid on coagulation as measured by thromboelastometry in term parturients: an in vitro study. J Matern Fetal Neonatal Med. 2021:1-8. DOI: 10.1080/14767058.2021.1929157
  221. Boyd C.J., Brainard B.M., Smart L. Intravenous Fluid Administration and the Coagulation System. Front Vet Sci. 2021; 8: 662504. DOI: 10.3389/fvets.2021.662504
  222. Schol P.B.B., de Lange N.M., Woiski M.D., et al. Restrictive versus liberal fluid resuscitation strategy, influence on blood loss and hemostatic parameters in mild obstetric hemorrhage: An open-label randomized controlled trial. (REFILL study). PLoS One. 2021; 16(6): e0253765. DOI: 10.1371/journal.pone.0253765
  223. Sevcikova S., Vymazal T., Durila M. Effect of Balanced Crystalloid, Gelatin and Hydroxyethyl Starch on Coagulation Detected by Rotational Thromboelastometry In Vitro. Clin Lab. 2017; 63(10): 1691–700. DOI: 10.7754/Clin.Lab.2017.170505
  224. Ho K.M., Leonard A.D. Concentration-dependent effect of hypocalcaemia on mortality of patients with critical bleeding requiring massive transfusion: a cohort study. Anaesth Intensive Care. 2011; 39(1): 46–54.
  225. Moore H.B., Tessmer M.T., Moore E.E., et al. Forgot calcium? Admission ionized-calcium in two civilian randomized controlled trials of prehospital plasma for traumatic hemorrhagic shock. J Trauma Acute Care Surg. 2020; 88(5): 588–96.DOI: 10.1097/TA.0000000000002614
  226. Byerly S., Inaba K., Biswas S., et al. Transfusion-Related Hypocalcemia After Trauma. World J Surg. 2020; 44(11): 3743–50. DOI: 10.1007/s00268-020-05712-x
  227. Chanthima P., Yuwapattanawong K., Thamjamrassri T., et al. Association Between Ionized Calcium Concentrations During Hemostatic Transfusion and Calcium Treatment With Mortality in Major Trauma. Anesth Analg. 2021; 132(6): 1684–91. DOI: 10.1213/ANE.0000000000005431
  228. Chung H.S., Cho S.J., Park C.S. Effects of liver function on ionized hypocalcaemia following rapid blood transfusion. J Int Med Res. 2012; 40(2): 572–82. DOI: 10.1177/147323001204000219
  229. Napolitano L.M. Hemostatic defects in massive transfusion: an update and treatment recommendations. Expert Rev Hematol. 2021; 14(2): 219–39.DOI: 10.1080/17474086.2021.1858788
  230. Ditzel R.M. Jr, Anderson J.L., Eisenhart W.J., et al. A review of transfusion- and trauma-induced hypocalcemia: Is it time to change the lethal triad to the lethal diamond? J Trauma Acute Care Surg. 2020; 88(3): 434–9. DOI: 10.1097/TA.0000000000002570
  231. Hall C., Nagengast A.K., Knapp C., et al. Massive transfusions and severe hypocalcemia: An opportunity for monitoring and supplementation guidelines. Transfusion. 2021; 61 Suppl 1: S188–S194. DOI: 10.1111/trf.16496
  232. DeBot M., Sauaia A., Schaid T., et al. Trauma-induced hypocalcemia. Transfusion. 2022; 62 Suppl 1: S274–S280. DOI: 10.1111/trf.16959
  233. Lier H., Krep H., Schroeder S., et al. Preconditions of hemostasis in trauma: a review. The influence of acidosis, hypocalcemia, anemia, and hypothermia on functional hemostasis in trauma. J Trauma. 2008; 65(4): 951–60. DOI: 10.1097/TA.0b013e318187e15b
  234. Perkins J.G., Cap A.P., Weiss B.M., et al. Massive transfusion and nonsurgical hemostatic agents. Crit Care Med. 2008; 36(7 Suppl): S325–39. DOI: 10.1097/CCM.0b013e31817e2ec5
  235. Rajagopalan S., Mascha E., Na J., et al. The effects of mild perioperative hypothermia on blood loss and transfusion requirement. Anesthesiology. 2008; 108(1): 71–7. DOI: 10.1097/01.anes.0000296719.73450.52
  236. Alam H.B., Pusateri A.E., Kindzelski A., et al. HYPOSTAT workshop participants. Hypothermia and hemostasis in severe trauma: A new crossroads workshop report. J Trauma Acute Care Surg. 2012; 73(4): 809–17. DOI: 10.1097/TA.0b013e318265d1b8
  237. Wang C.H., Chen N.C., Tsai M.S., et al. Therapeutic Hypothermia and the Risk of Hemorrhage: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore). 2015; 94(47): e2152. DOI: 10.1097/MD.0000000000002152
  238. Simegn G.D., Bayable S.D., Fetene M.B. Prevention and management of perioperative hypothermia in adult elective surgical patients: A systematic review. Ann Med Surg (Lond). 2021; 72: 103059. DOI: 10.1016/j.amsu.2021.103059
  239. Harvey C.J. Evidence-Based Strategies for Maternal Stabilization and Rescue in Obstetric Hemorrhage. AACN Adv Crit Care. 2018; 29(3): 284–94. DOI: 10.4037/aacnacc2018966
  240. Kander T., Schött U. Effect of hypothermia on haemostasis and bleeding risk: a narrative review. J Int Med Res. 2019; 47(8): 3559–68. DOI: 10.1177/0300060519861469
  241. Quine E.J., Murray L., Trapani T., et al. Thromboelastography to Assess Coagulopathy in Traumatic Brain Injury Patients Undergoing Therapeutic Hypothermia. Ther Hypothermia Temp Manag. 2021; 11(1): 53–7. DOI: 10.1089/ther.2020.0025
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2024 Annals of Critical Care

Most read articles by the same author(s)

1 2 3 4 5 6 > >>